Tag - Pyramid Biosciences

Pyramid Biosciences’ $864 Million Licensing Deal

Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up to $846 million. The licensing agreement with South Korea-based biotechnology company Voronoi, Inc. will bring a novel monopolar spindle1 (MPS1) called VRN-08 and second undisclosed asset into Pyramid Bioscience’s portfolio of precision oncology therapeutics. MPS1 is involved in core-of-tumor cell division. The novel inhibitor VRN-08 selectively blocks this process, ultimately leading to tumor cell death. Founded in 2015, Waltham, […]

Pyramid Biosciences Expands Precision Oncology Pipeline

Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the global licensing of the novel monopolar spindle1 (MPS1) called VRN-08 and a second undisclosed asset from Voronoi Inc., a South Korea-based biotechnology company the develops novel kinase inhibitors and target protein degraders. The milestone-based deal is worth up $846 million dollars (USD). Read more >>

Pyramid Biosciences Announces Initial Closing of Series B Financing for Clinical Program Acceleration

Pyramid Biosciences, Inc., a clinical stage, biotechnology company developing a portfolio of precision therapies targeting a wide range of molecularly-defined diseases, today announced the initial close of its Series B financing. The financing will support the clinical development of multiple programs focused on novel tropomyosin receptor kinase (TRK) modulators. The funding round was led by Oracle Investment Management, Inc., along with support from Adage Capital Management, Averill Master Fund, Ltd., J.W. Childs Associates L.P. as well as several other […]

Pyramid Biosciences Announces Leadership Team Expansion

Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced two new appointments to the leadership team.“We are looking forward to Dr. Lestini’s leadership of our clinical programs during this important growth stage of our company.” Brian Lestini, MD, PhD, has joined the company as Chief Medical Officer, where he will oversee the advancement and expansion of the Company’s clinical pipeline. Read more >>

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

Pyramid Biosciences, Inc. (www.pyramidbio.com), a Boston-based biotechnology company developing new therapies focused on the modulation of cell surface receptors today announced it has entered into an exclusive, worldwide licensing agreement with AstraZeneca PLC for the development and commercialization rights to a novel Tropomyosin receptor kinase (TRK) modulator, PBI-100. Read more >>